Cholesterol and inflammatory risk: Insights from secondary and primary prevention

Low-density lipoprotein cholesterol (LDL-C) is undeniably causal for cardiovascular disease (CVD) [1]. Evidence from both the FOURIER (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk) trial in patients with stable cardiovascular disease (CVD), and ODYSSEY Outcomes in acute coronary syndrome patients, supports a ‘lower is better’ strategy with no apparent lower threshold for benefit from LDL-C lowering. These data provide food for thought for guideline groups [2–4].

Source: Atherosclerosis - October 16, 2018 Category: Cardiology Authors: Jane Stock Tags: Discussion Source Type: research